311 related articles for article (PubMed ID: 7539179)
1. The role of prostate-specific antigen in the evaluation of benign prostatic hyperplasia.
Tchetgen MB; Oesterling JE
Urol Clin North Am; 1995 May; 22(2):333-44. PubMed ID: 7539179
[TBL] [Abstract][Full Text] [Related]
2. Molecular forms of serum prostate-specific antigen: the clinical usefulness of percent free PSA to discriminate prostate cancer from BPH.
Abrahamsson PA; Kuriyama M
Hinyokika Kiyo; 1998 Apr; 44(4):223-32. PubMed ID: 9617617
[TBL] [Abstract][Full Text] [Related]
3. Prostate specific antigen density for discriminating prostate cancer from benign prostatic hyperplasia in the gray zone of prostate-specific antigen.
Uno H; Koide T; Kuriyama M; Ban Y; Deguchi T; Kawada Y
Hinyokika Kiyo; 1999 Jul; 45(7):457-61. PubMed ID: 10466060
[TBL] [Abstract][Full Text] [Related]
4. Free to total prostate-specific antigen (PSA) ratio is superior to total-PSA in differentiating benign prostate hypertrophy from prostate cancer.
Van Cangh PJ; De Nayer P; Sauvage P; Tombal B; Elsen M; Lorge F; Opsomer R; Wese FX
Prostate Suppl; 1996; 7():30-4. PubMed ID: 8950361
[TBL] [Abstract][Full Text] [Related]
5. [Clinical significance of prostate specific antigen (PSA) and PSA density in the detection of T1a and T1b prostate cancer].
Meguro N; Maeda O; Saiki S; Kinouchi T; Kuroda M; Usami M; Kotake T
Hinyokika Kiyo; 1998 Sep; 44(9):639-43. PubMed ID: 9805668
[TBL] [Abstract][Full Text] [Related]
6. [Differential diagnostic value of prostate-specific antigen in prostatic hyperplasia].
Maksimov VA; Kamalov AA; Karpov VK; Riaboĭ AV; Prokhorov AV
Urologiia; 2001; (2):37-40. PubMed ID: 11490716
[TBL] [Abstract][Full Text] [Related]
7. Free to complexed PSA ratio in differentiating benign prostate hyperplasia from prostate cancer.
Filella X; Alcover J; Corral JM; Molina R; Beardo P; Ballesta AM
Anticancer Res; 2001; 21(5):3717-20. PubMed ID: 11848550
[TBL] [Abstract][Full Text] [Related]
8. [The percentage of free prostate specific antigen used in detecting prostate cancer].
Yang L; Fang Z; Song J; Deng S
Zhonghua Wai Ke Za Zhi; 1999 Jan; 37(1):47-9. PubMed ID: 11829778
[TBL] [Abstract][Full Text] [Related]
9. Increased discrimination between benign prostatic hyperplasia and prostate cancer through measurement of percentage free PSA.
Wolff JM; Boeckmann W; Effert PJ; Habib FK; Jakse G
Anticancer Res; 1997; 17(4B):2993-4. PubMed ID: 9329583
[TBL] [Abstract][Full Text] [Related]
10. The clinical value of the Enzymun-Test for total and free PSA--a multicentre evaluation.
Reiter W
Anticancer Res; 1999; 19(6C):5559-62. PubMed ID: 10697616
[TBL] [Abstract][Full Text] [Related]
11. [Serum and urine prostate-specific antigen ratio: its value in the distinction between prostate cancer and adenoma when serum prostate-specific antigen level is between 4 and 10 ng/ml].
Irani J; Millet C; Levillain P; Doré B; Bégon F; Aubert J
Chirurgie; 1997; 122(8-9):478-82. PubMed ID: 9616891
[TBL] [Abstract][Full Text] [Related]
12. Reference ranges for the concentrations of total and complexed plasma prostate-specific antigen and their ratio in patients with benign prostate hyperplasia.
España F; Martínez M; Royo M; Vera CD; Estellés A; Aznar J; Jiménez-Cruz JF
Eur Urol; 1997; 32(3):268-72. PubMed ID: 9358211
[TBL] [Abstract][Full Text] [Related]
13. Differential diagnosis of prostate cancer and benign prostate hyperplasia using two-dimensional electrophoresis.
Charrier JP; Tournel C; Michel S; Comby S; Jolivet-Reynaud C; Passagot J; Dalbon P; Chautard D; Jolivet M
Electrophoresis; 2001 May; 22(9):1861-6. PubMed ID: 11425243
[TBL] [Abstract][Full Text] [Related]
14. The ratio of free to total prostate specific antigen: an advantageous addition in the differential diagnosis of benign hyperplasia and cancer of the prostate?
Reiter W; Stieber P; Schmeller N; Nagel D; Jansen HM; Schambeck C; Fabricius PG; Pahl H; Mattes M; Constabel H; Fateh-Moghadam A
Anticancer Res; 1997; 17(4B):2987-91. PubMed ID: 9329582
[TBL] [Abstract][Full Text] [Related]
15. Determination of the "reflex range" and appropriate cutpoints for percent free prostate-specific antigen in 413 men referred for prostatic evaluation using the AxSYM system.
Vashi AR; Wojno KJ; Henricks W; England BA; Vessella RL; Lange PH; Wright GL; Schellhammer PF; Weigand RA; Olson RM; Dowell BL; Borden KK; Oesterling JE
Urology; 1997 Jan; 49(1):19-27. PubMed ID: 9000179
[TBL] [Abstract][Full Text] [Related]
16. [The quotient of prostate-specific antigen and prostate volume. Improved differentiation between benign prostatic hyperplasia and locally circumscribed prostate cancer].
Semjonow A; Hamm M; Rathert P
Urologe A; 1993 May; 32(3):250-3. PubMed ID: 7685557
[TBL] [Abstract][Full Text] [Related]
17. Serum sialic acid and prostate-specific antigen in differential diagnosis of benign prostate hyperplasia and prostate cancer.
Romppanen J; Haapalainen T; Punnonen K; Penttilä I
Anticancer Res; 2002; 22(1A):415-20. PubMed ID: 12017325
[TBL] [Abstract][Full Text] [Related]
18. Is screening for prostate cancer necessary in men with symptoms of benign prostatic hyperplasia?
Hall MC; Roehrborn CG; McConnell JD
Semin Urol Oncol; 1996 Aug; 14(3):122-33. PubMed ID: 8865473
[TBL] [Abstract][Full Text] [Related]
19. PSA density and PSA transition zone density in the diagnosis of prostate cancer in PSA gray zone cases.
Aksoy Y; Oral A; Aksoy H; Demirel A; Akcay F
Ann Clin Lab Sci; 2003; 33(3):320-3. PubMed ID: 12956448
[TBL] [Abstract][Full Text] [Related]
20. [The role of prostate specific antigen in diagnosis of localized adenocarcinoma of the prostate. Nara Uro-Oncology Research Group].
Hirao Y; Ozono S; Kagebayashi Y; Yoshi M; Tani Y; Uemura H; Momose H; Okajima E
Hinyokika Kiyo; 1996 Oct; 42(10):795-804. PubMed ID: 8951478
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
